Mayo Clinic Tests Radiation for Parkinson's Disease
Researchers are studying whether low-dose radiation can slow early-stage Parkinson's disease progression in a new clinical trial.
Updated on Oct. 21, 2026 in Stroke
Live Poll
Should medical researchers prioritize testing existing therapies on different diseases to find potential new treatments?
Mayo Clinic researchers have launched a clinical trial in Rochester to test the effects of low-dose radiation therapy on early-stage Parkinson's disease. The small study aims to determine if the treatment can reduce brain inflammation to help slow disease progression in adults aged 45 to 75.
Why it matters
Parkinson's disease is characterized by the loss of dopamine-producing cells and the buildup of abnormal proteins, and this trial investigates if radiation can modulate these underlying biological processes. By targeting inflammation, researchers hope to identify a novel method to manage symptoms and potentially impact the disease's long-term progression.
This clinical trial is a small-scale study of 20 participants with early-stage Parkinson's disease. Researchers are evaluating changes in inflammatory biomarkers and protein accumulation at intervals up to 12 months, though the study's preliminary nature means conclusive results are not yet available.
The players
Mayo Clinic
A nonprofit academic medical center and health system that conducts clinical trials and provides specialized neurological care.
The details
Researchers use brain imaging to map specific anatomy and plan precisely targeted radiation delivery sites. Participants receive low-dose treatment once daily for five consecutive days, with each individual session lasting 10 to 15 minutes. The therapy aims to address brain inflammation in regions affected by the disease.
Timeline
5 consecutive days of radiation treatment sessions.
6 hours post-treatment initial evaluation.
3, 6, and 12 months follow-up evaluations.
Health Landscape
This trial aligns with the broader medical effort to identify treatments that address the underlying biological drivers of neurodegenerative diseases rather than just managing symptoms. It adds to current research exploring how modulating brain inflammation may change the progression of Parkinson's disease.
This trial is currently limited to 20 invited participants and is not a general treatment option. Individuals managing early-stage Parkinson's disease should discuss current, evidence-based management strategies and clinical trial eligibility with their own neurologist.
The takeaway
Researchers are investigating whether low-dose radiation can effectively target brain inflammation in patients with Parkinson's disease. Those interested in emerging research should speak with their physician about how to monitor for new, peer-reviewed clinical trial opportunities in their area.
Further reading
For more information on the latest research and symptom management, visit Stroke.
Live Poll
Should medical researchers prioritize testing existing therapies on different diseases to find potential new treatments?
